Interestingly, a ROC curve used to determine the threshold for resistance/sensitivity to FET treatment using percentage change in FET-treated stromal Ki67 relative to vehicle control in BC-PDEs resulted in a ROC curve with an AUC of 0.69 (Fig. 5E) and showed a significant relationship (p = 0.007) between patients identified as sensitive/resistant (Fig. 5F). This evidence concerns the gene MKI67 and breast cancer.